AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium TranscriptSeeking Alpha • 02/13/26
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA SurpriseSeeking Alpha • 02/04/26
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)Seeking Alpha • 02/04/26
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/04/26
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugsReuters • 02/04/26